Dopamine-receptor stimulation: Biobehavioral and biochemical consequences

Trends in Neurosciences

Volumn 23, Issue 10 SUPPL., 2000, Pages

  Calon, Frédéric ^a,b   Tahar, Abdallah Hadj ^a,b   Blanchet, Pierre J ^a,b   Morissette, Marc ^a,b   Grondin, Richard ^a,b   Goulet, Martin ^a,b   Doucet, Jean Pierre ^c   Robertson, George S ^c   Nestler, Eric ^d   Di Paolo, Thérèse ^a,b   Bédard, Paul J ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; LEVODOPA;

ANIMAL EXPERIMENT; BASAL GANGLION; DOPAMINE BRAIN LEVEL; DRUG RECEPTOR BINDING; DYSKINESIA; MONKEY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW;

EID: 10644250114     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-1931(00)00026-4     Document Type: Review

References (86)

1. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines
2. Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism
3. Risk factors for peak dose dyskinesia in 100 L-dopa-treated parkinsonian patients
4. The spectrum of L-dopa-induced dyskinesias
5. Risk factors for L-dopa-induced dyskinesias in Parkinson's disease
6. L-dopa-induced dyskinesia: Review, observations, and speculations
7. The response to L-dopa in Parkinson's disease: Imposing pharmacological law and order
8. Investigating L-dopa-induced dyskinesias in the parkinsonian primate
9. L-dopa-induced dyskinesia and responsefluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
10. Is L-dopa toxic to human substantia nigra?
11. L-dopa and dyskinesias in normal monkeys
12. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA
13. Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease
14. Surgery for L-dopa-induced dyskinesias
15. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study
16. Inhibition of L-dopa effects by internal pallidal stimulation
17. Dyskinesias and the subthalamic nucleus
18. Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys
19. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis
20. Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what
21. Predictive reward signal of dopamine neurons
22. Thalamic interaction between the input and the output systems of the basal ganglia
23. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia- thalamo-cortical loop
24. Regulation of striatal dopamine release by metabotropic glutamate receptors
25. Inhibitory glutamatergic regulation of evoked dopamine release in striatum
26. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease
27. 3H]spiperone binding
28. L-dopa or D2 agonist induced dyskinesia in MPTP monkeys: Correlation with changes in dopamine and GABA(A) receptors in the striatopallidal complex
29. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys
30. Long-term treatment of Parkinson's disease with bromocriptine
31. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys
32. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys
33. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates
34. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates
35. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTPtreated marmoset
36. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated With ropinirole or L-dopa, 056 Study Group
37. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind L-dopa controlled trial. The PKDS009 Study Group
38. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys
39. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates
40. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys
41. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Correction with chronic administration of L-3,4-dihydroxyphenylalanine
42. Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958
43. L-dopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease
44. Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists
45. Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of parkinsonian monkeys
46. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: In situ hybridization histochemical analysis
47. A Golgi study of the human neostriatum: Neurons and afferent fibers
48. Glutamate decarboxylase immunoreactive neurons in rat neostriatum: Their morphological types and polutions
49. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones
50. L-dopa-induced dyskinesia: A pathological form of striatal synaptic plasticity?
51. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated
52. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum
53. Protein kinase A inhibitor attenuates L-dopa-induced motor response alterations in the hemi-parkinsonian rat
54. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: Effect of dopaminergic denervation and L-DOPA administration
55. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits
56. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease
57. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism
58. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model
59. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in L-dopatreated 1-methyl-4-phenyl- tetrahydropyridine monkeys
60. Modulation of L-dopa-induced motor response complications by NMDA antagonists in Parkinson's disease
61. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease
62. L-dopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys
63. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-DOPA therapy
64. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTPlesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists
65. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum
66. Dopamine-mediated gene regulation in models of Parkinson's disease
67. Dopamine regulation of transcription factor-target interactions in rat striatum
68. ΔFosB: A molecular mediator of long-term neural and behavioral plasticity
69. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of ΔFosB-like protein(s) in both the rodent and primate striatum
70. Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures
71. Molecular basis of L-dopa-induced dyskinesias
72. Improvement in tardive dyskinesia after muscimol therapy
73. GABA dysfunction in the pathophysiology of tardive dyskinesia
74. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment
75. Chronic D1 and D2 dopaminomimetic treatmenf of MPTP-denervated monkeys: Effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content
76. Chronic continuous and intermittent L-3,4-dihydroxyphenylalanine treatments differentially affect basal ganglia function in 6hydroxydopamine lesioned rats - An autoradiographic study using [3H]flunitrazepam
77. Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle
78. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: Evidence from [3H]flunitrazepam autoradiography
79. 125-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: Effect of MPTP and dopaminomimetic treatments
80. Primate models of movement disorders of basal ganglia origin
81. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism
82. The functional anatomy of basal ganglia disorders
83. Dopamine-receptor families and the treatment of Parkinson's disease
84. Pathophysiology of L-dopa-induced dyskinesias in Parkinson's disease: Problems with the current model
85. Internal globus pallidus discharge is nearly suppressed during levod L-dopa-induced dyskinesias
86. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl,1,2,3,6tetrahydropyridine-treated monkey